Coventry University Featured PhD Programmes
Imperial College London Featured PhD Programmes
Norwich Research Park Featured PhD Programmes
University of Dundee Featured PhD Programmes
Cardiff University Featured PhD Programmes

Bispecific monoclonal antibodies for cancer immunotherapy


Project Description

THE PROJECT
Monoclonal antibodies (MCAs) are now widely used for cancer therapy. DNA recombinant technology enables the production of MCAs that target cancer specific determinants and immune cells, attracting them to the cancer cells and so killing them. MCAs can now be produced that target intra-cellular proteins through attaching to protein fragments attached to HLA system proteins on the cell surface. This enables production of bispecific antibodies that kill cancer cells by recognition of intra cellular proteins. This project will involve the production and characterisation of such antibodies and their preclinical testing on our panel of colorectal cancer derived cell lines.

THE TRAINING
A combination of extensive cellular, molecular and immunological techniques with exposure to
statistical bioinformatics approaches to data analysis and modelling. Also, opportunities to work
with fresh human biopsy material for organoid production and to be involved in considerations of
clinical applications for treatment of colorectal and other cancers.

PUBLICATIONS
Neil Ashley, Trevor Yeung and Walter F Bodmer (2013) Stem cell differentiation and lumen
formation in colorectal, cancer cell lines and primary tumours. Cancer Res; 73(18); 5798–809.


Hsia L, Ashley N, Ouaret D, Wang L, Wilding J, Bodmer W F.(2016) Myofibroblasts are
distinguished from activated skin fibroblasts by the expression of AOC3 and other associated
markers. Proc Natl Acad Sci U S A 113(15):E2162 - 2171.


Marina Bacac et al (2016) A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for
the Treatment of Solid Tumors. Clinical Cancer Research. Published On line First February 9, 2016.
DOI: 10.1158/1078-0432.CCR-15-16

Funding Notes

All complete applications received by 12 noon (UK time) on Friday 11 January 2020 will automatically be considered for all relevant competitive University and funding opportunities, including the Clarendon Fund, Medical Research Council funding, and various College funds. Please refer to the Funding and Costs webpage (View Website) for this course for further details relating to funded scholarships and divisional funding opportunities.

Funded studentships are highly competitive and are awarded to the highest ranked applicant(s) based on the advertised entry requirements for each programme of study.

References

Whilst you must register three referees, the department may start the assessment of your application if two of the three references are submitted by the course deadline and your application is otherwise complete. Please note that you may still be required to ensure your third referee supplies a reference for consideration.

Academic references are strongly encouraged, though you may use up to one professional reference provided that it is relevant to the course.

How good is research at University of Oxford in Clinical Medicine?

FTE Category A staff submitted: 238.51

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities

Email Now

Insert previous message below for editing? 
You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need.
Why not add a message here
* required field
Send a copy to me for my own records.

Your enquiry has been emailed successfully





FindAPhD. Copyright 2005-2019
All rights reserved.